VOLUMATIC USAGE - SOME GENERIC SALBUTAMOL METERED-DOSE INHALERS CAN BE USED

被引:16
作者
CHEGE, JK [1 ]
CHRYSTYN, H [1 ]
机构
[1] UNIV BRADFORD,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND
关键词
D O I
10.1136/thx.49.11.1162
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background - The 30 minute and 24 hour post-inhalation urinary excretion of salbutamol represents the relative amount of drug deposited in the lungs and total systemic absorption, respectively. Using this method two metered dose inhalers used with a Volumatic (Alien and Hanburys Ltd, UK) large volume spacer have been compared. Method - Eleven healthy volunteers inhaled 4 x 100 mu g salbutamol from either a generic salbutamol (Baker Norton, UK) or Ventolin (Allen and Hanburys Ltd, UK) metered dose inhaler with a Volumatic. The order of administration was randomised with a seven day washout period. Urine samples were collected for 0-30 minutes and then pooled up to 24 hours after inhalation. Results - The mean (SD) urinary salbutamol excretion 30 minutes after inhalation with the metered dose inhalers used with the Volumatic was 22.22 (4.63) and 21.30 (5.91) mu g for the Baker Norton and Ventolin respectively, with a mean difference (95% confidence interval (CI)) of 0.92 (-0.65 to 2.49) mu g. Similar amounts were excreted up to 24 hours after the dose with a mean (SD) urinary excretion of 116.1 (24.3) mu g and 114.8 (22.3) mu g, respectively, and a mean difference (95% CI) of 1.22 (-20.39 to 22.84) mu g. Conclusion - Inhalations from generic salbutamol (Baker Norton) and Ventolin metered dose inhalers with a Volumatic inhalation aid deliver similar amounts of drug to the lungs and the total systemic absorption from the two products is the same.
引用
收藏
页码:1162 / 1163
页数:2
相关论文
共 11 条
[1]  
BELL JH, 1993, PHARM J, V251, P652
[2]   PULMONARY DEPOSITION OF INHALED TERBUTALINE - COMPARISON OF SCANNING GAMMA-CAMERA AND URINARY-EXCRETION METHODS [J].
BORGSTROM, L ;
NEWMAN, S ;
WEISZ, A ;
MOREN, F .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (08) :753-755
[3]   STANDARDS FOR BIOEQUIVALENCE OF INHALED PRODUCTS [J].
CHRYSTYN, H .
CLINICAL PHARMACOKINETICS, 1994, 26 (01) :1-6
[4]   SPACER DESIGN [J].
CRONIN, S .
LANCET, 1993, 342 (8883) :1361-1362
[5]   LOW 1ST-SPRAY DRUG CONTENT IN ALBUTEROL METERED-DOSE INHALERS [J].
CYR, TD ;
GRAHAM, SJ ;
LI, KYR ;
LOVERING, EG .
PHARMACEUTICAL RESEARCH, 1991, 8 (05) :658-660
[6]   DETERMINATION OF THE RELATIVE BIOAVAILABILITY OF SALBUTAMOL TO THE LUNG FOLLOWING INHALATION [J].
HINDLE, M ;
CHRYSTYN, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (04) :311-315
[7]   RELATIVE BIOAVAILABILITY OF SALBUTAMOL TO THE LUNG FOLLOWING INHALATION USING METERED-DOSE INHALATION METHODS AND SPACER DEVICES [J].
HINDLE, M ;
CHRYSTYN, H .
THORAX, 1994, 49 (06) :549-553
[8]  
HINDLE M, 1993, THORAX, V48, P611
[9]   EFFECT OF INHALED TERBUTALINE SULFATE IN RELATION TO ITS DEPOSITION IN THE LUNGS [J].
HULTQUIST, C ;
WOLLMER, P ;
EKLUNDH, G ;
JONSON, B .
PULMONARY PHARMACOLOGY, 1992, 5 (02) :127-132
[10]  
LEE MG, 1993, INT J PHARM PRACTICE, V2, P172